PDGFRB and cholangiocarcinoma: Given the significant inhibitory effect of the GSK3β and P65 inhibitors on tumor growth and LNM in CCA animal studies, we hypothesized that the PDGF-BB/PDGFR-β-GSK3β/P65 axis is a potential therapeutic target in CCA (Fig. 10B).